✦ LIBER ✦

Mycophenolate mofetil in dysimmune neuropathies: A preliminary study

✍ Scribed by Luana Benedetti; Marina Grandis; Lucilla Nobbio; Alessandro Beronio; Elisabetta Ghiglione; Marcello Manzino; Alberto Primavera; Gianluigi Mancardi; Angelo Schenone

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 48 KB
Volume: 29
Category: Article
ISSN: 0148-639X
DOI: 10.1002/mus.20024

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

In utero exposure to mycophenolate mofet

In utero exposure to mycophenolate mofetil: A characteristic phenotype?

✍ Antonio Perez-Aytes; Ana Ledo; Virginia Boso; Pilar Sáenz; Eva Roma; José Luis P 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB

## Abstract Mycophenolate mofetil (MMF) is a widely prescribed immunosuppressive agent after solid organ transplantation. Potential teratogenic effects after in utero exposure to MMF in experimental studies and clinical observations in humans has been postulated in recent literature. However, a spe

Mycophenolate mofetil for interstitial l

Mycophenolate mofetil for interstitial lung disease in dermatomyositis

✍ Pamela A. Morganroth; Mary Elizabeth Kreider; Victoria P. Werth 📂 Article 📅 2010 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 136 KB 👁 2 views

Conversion from mycophenolate mofetil to

Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: A pilot study

✍ Jérôme Dumortier; Marie-Claude Gagnieu; Janine Salandre; Olivier Guillaud; Phili 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

Gastrointestinal (GI) disorders are one of the main adverse events in patients treated by mycophenolic acid (MPA). The aim of this prospective study was to evaluate the effect of conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) in liver transplant patients

Stability and pharmacokinetic studies of

Stability and pharmacokinetic studies of a new immunosuppressant, mycophenolate mofetil (RS-61443), in rats

✍ Nobuyuki Sugioka; Shi Hu Chen; Kazuhisa Hayashida; Hikaru Koyama; Toshio Ohta; H 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 630 KB

A combination study design to examine my

A combination study design to examine mycophenolate mofetil (MMF) and PTLD in renal transplant patients

✍ Hilal Maradit Kremers; Donnie P. Funch; Richard A. Robson; Michael A. Nalesnik; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

Renal transplant recipients who are chronically immunosuppressed by drugs are at a higher risk of developing malignancies. Commonly observed malignancies are several forms of posttransplant lymphoproliferative disorders (PTLD), skin, lip and gynaecological cancers. The risk is associated with many r

Mycophenolate mofetil monotherapy in liv

Mycophenolate mofetil monotherapy in liver transplant recipients: A single center experience

✍ Kyrsten D. Fairbanks; Paul J. Thuluvath 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 1 views

The long-term use of calcineurin inhibitors (CIs) is associated with significant morbidity in liver transplant recipients. Although mycophenolate mofetil (MMF) is well tolerated, two small studies reported an unacceptable rate of acute allograft rejection in liver transplant recipients receiving MMF